

Grant McArthur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11698738/publications.pdf>

Version: 2024-02-01

15
papers

11,718
citations

759233

12
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

15321
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
2	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
3	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
4	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
5	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
6	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
7	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	30.5	417
8	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 216-227.	1.1	6
9	Targeted Therapies for Cutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 491-505.	2.2	11
10	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383.	1.6	216
11	BRAF, a target in melanoma. <i>Cancer</i> , 2010, 116, 4902-4913.	4.1	106
12	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. <i>Nature</i> , 2010, 468, 973-977.	27.8	1,944
13	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 188-198.	1.1	3
14	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	1.4	48
15	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 1329-1338.	13.7	2,349